Aktienanalyse zu Mesoblast Ltd (MESO)MESOMesoblast Ltd

Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Mesoblast Ltd is a good buy right now due to its impressive revenue growth of 600% year-over-year, reaching $120.3 million, and a positive analyst price target of $39, which indicates significant upside potential from the current price of $17.44. Additionally, the RSI is at 56.18, suggesting that the stock is neither overbought nor oversold, which is favorable for entry. However, the main risk is the high forward P/E ratio of 454.55, indicating that the stock may be overvalued if growth does not meet expectations.

6 analysts cover MESO: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 35.00.